237 related articles for article (PubMed ID: 1996743)
1. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay.
Barry M; Patterson JE; Tirrell S; Cullen MR; Shope RE
Am J Trop Med Hyg; 1991 Jan; 44(1):79-82. PubMed ID: 1996743
[TBL] [Abstract][Full Text] [Related]
2. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
[TBL] [Abstract][Full Text] [Related]
3. Use of MAC-ELISA for evaluation of yellow fever vaccination.
Nogueira RM; Schatzmayr HG; Miagostovich MP; Cavalcanti SM; de Carvalho R
Rev Inst Med Trop Sao Paulo; 1992; 34(5):447-50. PubMed ID: 1342109
[TBL] [Abstract][Full Text] [Related]
4. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination.
Vázquez S; Valdés O; Pupo M; Delgado I; Alvarez M; Pelegrino JL; Guzmán MG
J Virol Methods; 2003 Jun; 110(2):179-84. PubMed ID: 12798246
[TBL] [Abstract][Full Text] [Related]
5. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine.
Stefano I; Sato HK; Pannuti CS; Omoto TM; Mann G; Freire MS; Yamamura AM; Vasconcelos PF; Oselka GW; Weckx LW; Salgado MF; Noale LF; Souza VA
Vaccine; 1999 Mar; 17(9-10):1042-6. PubMed ID: 10195613
[TBL] [Abstract][Full Text] [Related]
6. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.
Niedrig M; Lademann M; Emmerich P; Lafrenz M
Trop Med Int Health; 1999 Dec; 4(12):867-71. PubMed ID: 10632996
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
8. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine does not adversely affect the antibody response to yellow fever vaccine.
Tsai TF; Bolin RA; Lazuick JS; Miller KD
J Infect Dis; 1986 Oct; 154(4):726-7. PubMed ID: 3745979
[No Abstract] [Full Text] [Related]
10. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.
Lang J; Zuckerman J; Clarke P; Barrett P; Kirkpatrick C; Blondeau C
Am J Trop Med Hyg; 1999 Jun; 60(6):1045-50. PubMed ID: 10403341
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.
Camacho LA; Freire Mda S; Leal Mda L; Aguiar SG; Nascimento JP; Iguchi T; Lozana Jde A; Farias RH;
Rev Saude Publica; 2004 Oct; 38(5):671-8. PubMed ID: 15499438
[TBL] [Abstract][Full Text] [Related]
13. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.
Mason RA; Tauraso NM; Spertzel RO; Ginn RK
Appl Microbiol; 1973 Apr; 25(4):539-44. PubMed ID: 4633476
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical study of a new 17D thermostable yellow fever vaccine.
Roche JC; Jouan A; Brisou B; Rodhain R; Fritzell B; Hannoun C
Vaccine; 1986 Sep; 4(3):163-5. PubMed ID: 3532602
[TBL] [Abstract][Full Text] [Related]
15. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
16. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine.
Kayser M; Klein H; Paasch I; Pilaski J; Blenk H; Heeg K
J Med Virol; 1985 Sep; 17(1):35-45. PubMed ID: 2995571
[TBL] [Abstract][Full Text] [Related]
17. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a purified fragment of 17D yellow fever envelope protein.
Brandriss MW; Schlesinger JJ; Walsh EE
J Infect Dis; 1990 Jun; 161(6):1134-9. PubMed ID: 1693159
[TBL] [Abstract][Full Text] [Related]
19. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
Barrett ADT
Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
Wieten RW; Jonker EF; Pieren DK; Hodiamont CJ; van Thiel PP; van Gorp EC; de Visser AW; Grobusch MP; Visser LG; Goorhuis A
Vaccine; 2016 Mar; 34(10):1247-51. PubMed ID: 26845742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
